The Biospecimen Repository Core is designed to provide support to the basic translational research efforts ofthe SPORE. The Core will play a central role in collecting, annotating, storing, distributing, and tracking thyroid cancer tissue and blood biospecimens from patients enrolled in research protocols. Detailed biospecimen annotation, including documentation of pre-analytic processing variables, pathology findings, and patient clinical history information will be recorded in relational databases. We will conduct rigorous data quality assurance and quality control measures of all consented patients with materials in the thyroid biospecimen repository. The Core will provide SPORE investigators with expert histopathological evaluation of tumor samples both from patients enrolled on research protocols and from animal models. The Core will also provide assistance In performing and interpreting immunohistochemical assays, in selecting tissue for microdissection and construction of arrays. We will also provide targeted cancer gene sequencing of thyroid carcinomas using exon capture by hybridization followed by next-generation sequencing.
Specific Aim 1 : To maintain and expand the collection, annotation, and storage of bio-specimens for thyroid carcinoma translational research.
Specific Aim 2 : To perform expert pathologic evaluation of all human and animal thyroid carcinomas samples and preparation of appropriate tissues for use by SPORE investigators.
Specific Aim 3 : To provide targeted cancer gene sequencing of thyroid carcinomas using exon capture by hybridization followed by next-generation sequencing. The Core will serve as a focal point to help integrate and prioritize a variety of institutional pathology systems-related development efforts, and we plan to document and publish our findings, standard operating procedures, and best practices, to better serve the research community. Core 1 will serve RP1, RP2, RP3 and RP4, PP1, PP2, PP4 and PPS.

Public Health Relevance

The Thyroid Cancer SPORE, supported by the Biospecimen Repository Core, aims to increase our understanding ofthe clinical, biologic, and genetic basis of thyroid cancer in an effort to improve patient outcomes, to facilitate a range of scientific activities that could lead to new genomic- and proteomic-based interventions for cancer, including target identification, validation, and development of new biomarkers and diagnostic analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA172012-01A1
Application #
8738873
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (M1))
Project Start
2014-09-19
Project End
2019-08-31
Budget Start
2014-09-19
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
$135,218
Indirect Cost
$48,998
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Ganly, Ian; Makarov, Vladimir; Deraje, Shyamprasad et al. (2018) Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell 34:256-270.e5
De Martino, Daniela; Yilmaz, Emrullah; Orlacchio, Arturo et al. (2018) PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett 439:56-65
Marlow, Laura A; Rohl, Stephen D; Miller, James L et al. (2018) Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. J Clin Endocrinol Metab 103:3169-3182
Krishnamoorthy, Gnana P; Davidson, Natalie R; Leach, Steven D et al. (2018) EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discov :
Untch, Brian R; Dos Anjos, Vanessa; Garcia-Rendueles, Maria E R et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res 78:4642-4657
Knauf, Jeffrey A; Luckett, Kathleen A; Chen, Kuen-Yuan et al. (2018) Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. J Clin Invest 128:4086-4097
Anelli, Viviana; Villefranc, Jacques A; Chhangawala, Sagar et al. (2017) Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression. Elife 6:
Tuttle, R Michael; Fagin, James A; Minkowitz, Gerald et al. (2017) Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngol Head Neck Surg 143:1015-1020
Xu, Bin; Tuttle, R Michael; Sabra, Mona M et al. (2017) Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics. Thyroid 27:632-640
Montero-Conde, Cristina; Leandro-Garcia, Luis J; Chen, Xu et al. (2017) Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proc Natl Acad Sci U S A 114:E4951-E4960

Showing the most recent 10 out of 53 publications